ArticlemBio2025
Near extinction of the HBV quasispecies driven by the hard selective sweep in chronic hepatitis B.
Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The viral quasispecies play an important role in pathogenesis. However, little is known about the nature of hepatitis B virus (HBV) quasispecies and its impact on the outcomes of chronic hepatitis B. Here, we characterized the bona fide quasispecies viral populations from 16 chronically infected patients by analyzing the near full-length viral genomes obtained by single genome sequencing. Follow-up plasma samples were collected from six patients after 6 months and from four patients after 3-5 years. We found that the viral population diversity levels were highly variable among these patients, depending on the status of the selection pressure. To further understand the host selection pressure over time, we compared viral sequences from different timepoints in 10 patients and found the hard selective sweep (HSS) at the whole genome level in three of them. This HSS was extremely strong and drove the highly diversified viral quasispecies into a distinct yet homogeneous viral population in each patient after 1-4 years of infection. The identical or nearly identical sequences in the homogeneous viral population indicate that they originate from a single infected source. Predominant and fixed mutations were observed in well-characterized T cell epitopes but not in known epitopes of neutralizing antibodies or N-linked glycosylation sites. Since HSS is strong enough to drive HBV quasispecies into near extinction and frequently occurs in chronic hepatitis B patients, this raises the hope for eliminating HBV from the last single reservoir through enhancing specific T cell immune responses targeting the highly selected homogeneous viruses.IMPORTANCEThe nature of bona fide hepatitis B virus (HBV) quasispecies and its potential impact on the outcomes of chronic hepatitis B are not well understood. Analysis of the high-quality near full-length HBV sequences from chronic hepatitis B patients identifies the strong hard selective sweep that can drive the viral quasispecies into a distinct yet highly homogeneous viral population. The nearly identical viral population suggests that all these viruses are from a single source. Predominant mutations were identified in known T cell epitopes but not in epitopes for neutralizing antibodies, indicating that the hard selective sweep is most likely driven by T cell selection pressure. These findings indicate that enhancement of specific T cell responses during chronic hepatitis B can easily eliminate the highly homogeneous viral population and serve as a promising approach to achieve the goal of a functional cure for chronic hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.